Seelos Therapeutics Inc
NASDAQ:SEEL
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Seelos Therapeutics Inc
NASDAQ:SEEL
|
100k USD |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
948.8B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
563B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
282B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
214.9B GBP |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
288.1B USD |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
225.6B CHF |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.6T DKK |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
146.4B USD |
Loading...
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
98B EUR |
Loading...
|
Market Distribution
| Min | -4 418 600% |
| 30th Percentile | -9.6% |
| Median | 3.1% |
| 70th Percentile | 11.3% |
| Max | 1 135 400% |
Other Profitability Ratios
Seelos Therapeutics Inc
Glance View
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in New York City, New York and currently employs 15 full-time employees. The firm is focused on the development of products that address unmet needs in central nervous system (CNS) disorders and other rare disorders. The firm's lead programs SLS-002 for the treatment of acute suicidal ideation and behavior (ASIB) in depressive disorder (MDD), and SLS-005 for the potential treatment of amyotrophic lateral sclerosis (ALS). SLS-005 for the potential treatment of Sanfilippo Syndromes, which is being explored. The company is also developing several preclinical programs, including SLS-010, an oral histamine H3A receptor antagonist that shows promising activity in narcolepsy and related disorders, and SLS-012, an injectable therapy for post-operative pain management. The firm's ongoing programs include SLS-004, SLS-006, SLS-007 and SLS-008.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Seelos Therapeutics Inc is 203.1%, which is above its 3-year median of -3 718.8%.
Over the last 1 years, Seelos Therapeutics Inc’s Net Margin has increased from -9 030.2% to 203.1%. During this period, it reached a low of -9 030.2% on Mar 31, 2023 and a high of 203.1% on Jul 30, 2024.
